Butizide


Generic Medicine Info
Indications and Dosage
Oral
Oedema
Adult: 5-10 mg daily, may be used with other diuretics.

Oral
Hypertension
Adult: 2.5-7.5 mg daily, may be used with other antihypertensives.
Contraindications
Severe hepatic impairment and renal decompensation. Addison's disease.
Special Precautions
Existing fluid and electrolyte disturbances, patients who are at risk from changes in fluid and electrolytes. DM, hypercholesterolaemia, SLE, may precipitate gout.
Adverse Reactions
Orthostatic hypotension, Photosensitivity, hypokalaemia, anorexia, epigastric distress.
Drug Interactions
Concurrent use with colestipol and cholestyramine may reduce absorption of butizide. Ciclosporin can potentiate the risk of renal toxicity and gout. Efficacy may be reduced by NSAIDs. May enhance toxicity of cardiac glycosides and risk of arrhythmias associated with drugs that prolong QT interval. May increase neuromuscular blocking action of competitive neuromuscular blockers e.g. atracurium. Hypokalaemic effect may be potentiated by corticosteroids, corticotropin, β2 agonists, carbenoxolone, amphotericin B or reboxetine. Concurrent use with lithium may lead to lithium toxicity.
Action
Description: Butizide is a thiazide diuretic that works by inhibiting sodium reabsorption in the distal tubules, resulting in increased excretion of sodium and water as well as potassium and hydrogen ions. It is used in the treatment of oedema and hypertension.
MIMS Class
Diuretics
Disclaimer: This information is independently developed by MIMS based on Butizide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in